Selected Summary
NASH Remains Without a Treatment … URSO They Say
Jeffrey B. Schwimmer MD,
Jeffrey B. Schwimmer MD
University of California, San Diego, California
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children’s Hospital and Health Center, Fatty Liver Clinic, San Diego, California
Search for more papers by this author Christian Braegger M.D., Warren P. Bishop M.D., Steven N. Lichtman M.D., Joel R. Rosh M.D., Jonathan E. Teitlebaum M.D.,
Jeffrey B. Schwimmer MD,
Jeffrey B. Schwimmer MD
University of California, San Diego, California
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Children’s Hospital and Health Center, Fatty Liver Clinic, San Diego, California
Search for more papers by this author Christian Braegger M.D., Warren P. Bishop M.D., Steven N. Lichtman M.D., Joel R. Rosh M.D., Jonathan E. Teitlebaum M.D.,
First published: 01 September 2004
No abstract is available for this article.
REFERENCES
- 1Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770–8.
- 2Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437–43.
- 3Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995; 20: 127–30.
- 4Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464–7.
- 5Schwimmer JB, Deutsch R, Rauch JB, et al. Obesity, insulin resistance, and other clinicopathologic correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143: 500–5.
- 6Vajro P, Franzese A, Valerio G, et al. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739–43.
